Pharma Focus Asia

Abzena Invests US$5 million to Expands its Manufacturing Site in Pennsylvania, USA


Abzena invests US$5 million to expand its bioconjugate development and cGMP manufacturing site in Pennsylvania, USA.


The investment in expanding laboratory space, acquiring new equipment, and upgrading facilities enhances the existing bioconjugation capabilities of the site and augments its capacity to support comprehensive biopharmaceutical drug programmes.

As part of this expansion initiative, the investments in five cutting-edge Waters Arc Premier LC Systems and two ACQUITY Premier Chromatography Systems, are made aiming to ensure consistent and reliable product analysis from the initial development phases through cGMP release and stability testing.

The recent investment significantly boosts the Bristol facility by expanding and optimising its quality control (QC) and analytical laboratory configurations and technologies, leading to enhanced efficiencies.

Furthermore, the site has undergone comprehensive renovations in its non-laboratory areas, which involve the installation of new flooring, implementation of modern lighting systems, and revitalisation of communal spaces. 

These efforts aim to enhance efficiencies and enhance the working environment for colleagues.


Name      Abzena
Type        Expansion
Budget    US$5 million

magazine-slider-imageCytiva - Supor Prime filtersMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference